371
Views
79
CrossRef citations to date
0
Altmetric
Original Article

Cancer Incidence after Radiotherapy for Skin Haemangioma During Infancy

, , , , &
Pages 735-740 | Accepted 22 Jun 1995, Published online: 08 Jul 2009
 

Abstract

An infant cohort treated for skin haemangioma with 226Ra between 1930 and 1965 (n = 11 807) was studied. The median age at treatment was 5 months and 88% were treated before 12 months of age. This cohort was followed up in the Swedish Cancer Registry during the years 1958 to 1989, giving 370 517 person-years at risk. A total number of 248 malignancies have been observed and the standardized incidence ratio (SIR) was 1.21 (confidence interval (CI) 95%, 1.06–1.37). Significantly increased numbers of cancers were found in the central nervous system, 34 cases (SIR = 1.85, CI 95% 1.28–2.59), the thyroid, 15 cases (SIR = 1.88, CI 95% 1.05–3.09) and other endocrine glands, 23 cases (SIR = 2.58, CI 95% 1.64–3.87). The absorbed dose in 11 specified risk organs has been estimated using a phantom of the size of a 5–6–month-old child. The mean absorbed dose in the thyroid was 0.12 Gy and the excess relative risk (ERR) for thyroid cancer was 7.5 per Gy (CI 95% 0.4–18.1). The mean dose in the central nervous system was 0.077 Gy and the ERR for brain tumours was 10.9 per Gy (CI 95% 3.7–20.5). This cohort gives a unique opportunity to analyse long-term effects of low-dose irradiation during infancy.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.